IP Library › Granted Patent US 12,600,784
Granted Patent B2
US 12,600,784 · App. 17/728,664 · Granted Apr 14, 2026

Anti-Clec12A antibodies and uses thereof

Inventor: Tomoki Yoshihara (Cambridge, MA)
Assignee: Millennium Pharmaceuticals, Inc.
C07K16/2851A61K39/3955A61P35/00C07K2317/21C07K2317/33C07K2317/565C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,784
App. No.
17/728,664
Granted
Apr 14, 2026
Kind
B2
Abstract

Antibodies, fragments thereof and fusion proteins that specifically bind to Clec12A, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including leukemia, lymphoma, or myeloma, including, for example, acute myeloid leukemia.

Claims (73)

1 . An anti-Clec12A antibody or antigen-binding fragment thereof comprising:

(a) a heavy chain complementarity determining region (HCDR) 1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO: 19), an HCDR2 comprising an amino acid sequence of IYYSGST (SEQ ID NO: 20), an HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO: 21); and

a light chain complementarity determining region (LCDR) 1 comprising an amino acid sequence of QGIRYD (SEQ ID NO: 22), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO:23), and an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO: 24); or

(b) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO: 73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO: 25), and HCDR3 comprising an amino acid sequence of ARDKGYYFDY (SEQ ID NO: 26); and

an LCDR1 comprising an amino acid sequence of QSVGNRY (SEQ ID NO: 27), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO: 28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29); or

(c) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO: 73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO: 25), an HCDR3 comprising an amino acid sequence of ARDGSRYFDY (SEQ ID NO: 30); and

an LCDR1 comprising an amino acid sequence of QSVHSKY (SEQ ID NO: 31), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO: 28), an LCDR3 comprising an amino acid sequence of QQDYNLPIT (SEQ ID NO: 32); or

(d) an HCDR1 comprising an amino acid sequence of GGSISSSTYY (SEQ ID NO: 33), an HCDR2 comprising an amino acid sequence of THYRGST (SEQ ID NO: 34), an HCDR3 comprising an amino acid sequence of ARELTGEVFDY (SEQ ID NO: 35); and

an LCDR1 comprising an amino acid sequence of QSISSY (SEQ ID NO:36), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO: 23), an LCDR3 comprising an amino acid sequence of QQSYSTPFT (SEQ ID NO: 37); or

(e) an HCDR1 comprising an amino acid sequence of GGSISTYY (SEQ ID NO: 19), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO: 38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21); and

an LCDR1 comprising an amino acid sequence of QGIRND (SEQ ID NO: 39), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO: 23), an LCDR3 comprising an amino acid sequence of LQDYNYPRT (SEQ ID NO:40); or

(f) an HCDR1 comprising an amino acid sequence of GGSISTDY (SEQ ID NO:41), an HCDR2 comprising an amino acid sequence of IYFSGST (SEQ ID NO:38), and HCDR3 comprising an amino acid sequence of AREDYYGSGSPFDY (SEQ ID NO:21); and

an LCDR1 comprising an amino acid sequence of QDIRND (SEQ ID NO:42), an LCDR2 comprising an amino acid sequence of AAS (SEQ ID NO: 23), an LCDR3 comprising an amino acid sequence of LQDYNFPRT (SEQ ID NO: 24); or

(g) an HCDR1 comprising an amino acid sequence of GFTFSSYG (SEQ ID NO: 73), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO:25), and HCDR3 comprising an amino acid sequence of ARDGQFYFDY (SEQ ID NO: 43); and

an LCDR1 comprising an amino acid sequence of QSVTSRY (SEQ ID NO:44), an LCDR2 comprising an amino acid sequence of GAS (SEQ ID NO:28), an LCDR3 comprising an amino acid sequence of QQDYNLPLT (SEQ ID NO:29); or

(h) an HCDR1 comprising an amino acid sequence of GFTFSNYG (SEQ ID NO: 45), an HCDR2 comprising an amino acid sequence of ISYDGSDK (SEQ ID NO: 25), and HCDR3 comprising an amino acid sequence of ARDSGRYFFDY (SEQ ID NO:46); and

an LCDR1 comprising an amino acid sequence of QSVSSRS (SEQ ID NO:47), an LCDR2 comprising an amino acid sequence of GPS (SEQ ID NO: 48), an LCDR3 comprising an amino acid sequence of HQDYNLPLT (SEQ ID NO:49); or

(i) an HCDR1 comprising an amino acid sequence of GFTFSKYG (SEQ ID NO: 50), an HCDR2 comprising an amino acid sequence of IWYDGSIK (SEQ ID NO: 51), and HCDR3 comprising an amino acid sequence of ARGSLWFGEFYFDY (SEQ ID NO: 52); and

an LCDR1 comprising an amino acid sequence of QGISSA (SEQ ID NO: 53), an LCDR2 comprising an amino acid sequence of DAS (SEQ ID NO: 54), an LCDR3 comprising an amino acid sequence of QQFNNYPRT (SEQ ID NO: 55).

2 . The anti-Clec12A antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-Clec12A antibody or fragment thereof is a monoclonal antibody or a single-chain variable fragment (scFv).

3 . The anti-Clec12A antibody or antibody-binding fragment thereof of claim 2 , wherein the scFv comprises a heavy chain variable sequence, a GS-Linker, and a light chain variable sequence.

4 . The anti-Clec12A antibody or antigen-binding fragment thereof of claim 3 , wherein the scFv comprises a sequence having at least 80% identity to:

(d) SEQ ID NO: 56;

(e) SEQ ID NO: 57;

(f) SEQ ID NO: 58; or

(g) SEQ ID NO: 59.

5 . The anti-Clec 12A antibody or antigen-binding fragment thereof of claim 4 , wherein the scFv comprises a sequence selected from:

(a) SEQ ID NO: 56;

(b) SEQ ID NO: 57;

(c) SEQ ID NO: 58; and

(d) SEQ ID NO: 59.

6 . The anti-Clec12A antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-Clec12A antibody is an antibody comprising an IgG constant region.

7 . A nucleic acid sequence encoding the amino acid sequence of the anti-Clec12A antibody or antigen-binding fragment thereof of claim 1 .

8 . A vector comprising the nucleic acid sequence of claim 7 .

9 . A cell comprising the vector of claim 8 .

10 . The anti-Clec12A antibody or antigen-binding fragment thereof according to claim 1 , comprising:

(a) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 2; or

(b) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 3, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 4; or

(c) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 5, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 6; or

(d) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 7, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 8; or

(e) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 9, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 10; or

(f) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 11, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 12; or

(g) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 13, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 14; or

(h) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 15, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 16; or

(i) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 17, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 18.

11 . The anti-Clec12A antibody or antigen-binding fragment thereof according to claim 10 , comprising:

(a) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 1, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence of SEQ ID NO: 2; or

(b) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 3, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence of SEQ ID NO: 4; or

(c) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 5, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence of SEQ ID NO: 6; or

(d) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 7, and

an immunoglobulin light chain variable (VL) region comprising an amino acid sequence of SEQ ID NO: 8; or

(e) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 9, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence of SEQ ID NO: 10; or

(f) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 11, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence of SEQ ID NO: 12; or

(g) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 13, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence of SEQ ID NO: 14; or

(h) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 15, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence of SEQ ID NO: 16; or

(i) an immunoglobulin heavy chain variable (VH) region comprising an amino acid sequence of SEQ ID NO: 17, and

an immunoglobulin light variable (VL) region comprising an amino acid sequence of SEQ ID NO: 18.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2023
From: YOSHIHARA, TOMOKI
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 064968/0769 →
Continuity (2)
Provisional Application 63179755 · Apr 26, 2021
Related Publication 20230111279A1 · Apr 13, 2023
References Cited (33)
US 10358492B2 · Bakker et al. · 2019 [cited by applicant]
US 20200277384A1 · Chang et al. · 2020 [cited by applicant]
US 20200345779A1 · Davila · 2020 [cited by examiner]
US 20200347139A1 · Rascon et al. · 2020 [cited by applicant]
US 20200384084A1 · Bakker et al. · 2020 [cited by applicant]
US 20220363775A1 · Sadelain · 2022 [cited by examiner]
CA 3088878A1 · 2019 [cited by applicant]
CL 201700590A1 · 2017 [cited by applicant]
CL 202203077A1 · 2022 [cited by applicant]
CL 2023003185A1 · 2024 [cited by applicant]
CL 2020003174A1 · 2024 [cited by applicant]
WO 2016040868A1 · 2016 [cited by applicant]
WO WO2020140088A1 · 2020 [cited by examiner]
WO 2021226193A1 · 2021 [cited by applicant]
WO 2022232016A2 · 2022 [cited by applicant]
WO 2022232035A1 · 2022 [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/026175 dated Nov. 11, 2022 (19 pages). [cited by applicant]
Morsink, Linde M., et al., “Novel monoclonal antibody-based therapies for acute myeloid leukemia”, Best Practice & Research Clinical Haematology, vol. 32, No. 2, Jun. 2019, pp. 116-126, DOI: 10.1016/j.beha.2019.05.002 (… [cited by applicant]
Noordhuis, Paul, et al., “Targeting of CLEC12A in Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody”, Blood, vol. 116, No. 21, Nov. 19, 2010, pp. 2890, DOI: 10.1182/blood. V116.21… [cited by applicant]
Dondelinger, et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition”, Frontiers in Immunology, Oct. 16, 2018; vol. 9, DOI:10.3389/fimmu.2018.02278 X… [cited by applicant]
Kussie, et al., “A Single Engineered Amino Acid Substitution Changes Antibody Specificity”, The Journal of Immunology, Jan. 1, 1994; 152 (1): https://doi.org/10.4049/jimmunol.152.1.146, pp. 146-152 (8 pages). [cited by applicant]
Liu, et al., “Fine Mapping of the Antigen-Antibody Interaction of Scfv215, A Recombinant Antibody Inhibiting RNA Polymerase II from [cited by applicant]
Panka, et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies”, Proceedings of the National Academy of Sciences of the United States of America; vol. … [cited by applicant]
Rudikoff, et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Proceedings of the National Academy of Sciences USA, Immunology, vol. 79, Mar. 1982, pp. 1979-1983 (5 pages). [cited by applicant]
Sela-Culang, et al., “The Structural Basis of Antibody-Antigen Recognition”, Frontiers in Immunology, Oct. 8, 2013, vol. 4, doi:10.3389/fimmu.2013.00302, XP055557261 DOI: http://dx.doi.org/10.3389/fimmu.2013.00302; pp. … [cited by applicant]
Wong, et al., “Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determining … [cited by applicant]
Xiang, et al., “Modification in Framework Region I Results in a Decreased Affinity of Chimeric Anti-TAG72 Antibody”, Molecular Immunology 28(1-2) Jan.-Feb. 1991; DOI: 10.1016/0161-5890(91)90097-4; https://doi.org/10.101… [cited by applicant]
Bostrom, et al., “Improving Antibody Binding Affinity and Specificity for Therapeutic Development”, Methods Molecular Biology, 2009; 525:353-76, xiii. DOI: 10.1007/978-1-59745-554-1_19, pp. 353-376 (24 pages). [cited by applicant]
Frenzel, et al., “Chapter 6: Antibody Affinity”, Handbook of Therapeutic Antibodies, First published: Aug. 12, 2014, https://DOI.org/10.1002/9783527682423.ch6, pp. 115-139 (25 pages). [cited by applicant]
Gonzales, et al: “Minimizing the Immunogenicity of Antibodies for Clinical Application”; Tumour Biology, Jan.-Feb. 2005; 26(1):31-43. DOI: 10.1159/000084184, pp. 31-43 (13 pages). [cited by applicant]
Kunik, et al., “Structural Consensus Among Antibodies Defines the Antigen Binding Site”, PLoS Computational Biology, Feb. 2012, vol. 8 Issue 2 DOI: 10.1371/journal.pcbi.1002388, www.ploscompbiol.org, pp. 1-12 (12 pages). [cited by applicant]
Wark, et al., “Latest Technologies for the Enhancement of Antibody Affinity”, Advanced Drug Delivery Reviews, Elsevier, Jan. 25, 2006, vol. 58, No. 5-6, DOI:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (Aug. 7, 2006), pp… [cited by applicant]
Wu, et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”, Journal of Molecular Biology, 1999, 294, www.idcalibrary.com pp. 151-162 (12 pages). [cited by applicant]